JP2007520494A5 - - Google Patents

Download PDF

Info

Publication number
JP2007520494A5
JP2007520494A5 JP2006551599A JP2006551599A JP2007520494A5 JP 2007520494 A5 JP2007520494 A5 JP 2007520494A5 JP 2006551599 A JP2006551599 A JP 2006551599A JP 2006551599 A JP2006551599 A JP 2006551599A JP 2007520494 A5 JP2007520494 A5 JP 2007520494A5
Authority
JP
Japan
Prior art keywords
subject
composition
molecule
red blood
type iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006551599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007520494A (ja
Filing date
Publication date
Priority claimed from US10/771,552 external-priority patent/US20050169921A1/en
Application filed filed Critical
Publication of JP2007520494A publication Critical patent/JP2007520494A/ja
Publication of JP2007520494A5 publication Critical patent/JP2007520494A5/ja
Withdrawn legal-status Critical Current

Links

JP2006551599A 2004-02-03 2005-02-03 溶血性疾患の処置方法 Withdrawn JP2007520494A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/771,552 US20050169921A1 (en) 2004-02-03 2004-02-03 Method of treating hemolytic disease
PCT/US2005/003225 WO2005074607A2 (en) 2004-02-03 2005-02-03 Method of treating hemolytic disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011065075A Division JP2011126917A (ja) 2004-02-03 2011-03-23 溶血性疾患の処置方法

Publications (2)

Publication Number Publication Date
JP2007520494A JP2007520494A (ja) 2007-07-26
JP2007520494A5 true JP2007520494A5 (enExample) 2008-03-27

Family

ID=34808492

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2006551599A Withdrawn JP2007520494A (ja) 2004-02-03 2005-02-03 溶血性疾患の処置方法
JP2011065075A Withdrawn JP2011126917A (ja) 2004-02-03 2011-03-23 溶血性疾患の処置方法
JP2013145341A Expired - Lifetime JP5873047B2 (ja) 2004-02-03 2013-07-11 溶血性疾患の処置方法
JP2015015028A Withdrawn JP2015083611A (ja) 2004-02-03 2015-01-29 溶血性疾患の処置方法
JP2017000897A Pending JP2017057234A (ja) 2004-02-03 2017-01-06 溶血性疾患の処置方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2011065075A Withdrawn JP2011126917A (ja) 2004-02-03 2011-03-23 溶血性疾患の処置方法
JP2013145341A Expired - Lifetime JP5873047B2 (ja) 2004-02-03 2013-07-11 溶血性疾患の処置方法
JP2015015028A Withdrawn JP2015083611A (ja) 2004-02-03 2015-01-29 溶血性疾患の処置方法
JP2017000897A Pending JP2017057234A (ja) 2004-02-03 2017-01-06 溶血性疾患の処置方法

Country Status (16)

Country Link
US (5) US20050169921A1 (enExample)
EP (7) EP2910253A1 (enExample)
JP (5) JP2007520494A (enExample)
KR (1) KR101197799B1 (enExample)
CN (4) CN103977403A (enExample)
AU (1) AU2005209854B2 (enExample)
CA (1) CA2554632A1 (enExample)
CY (1) CY1113190T1 (enExample)
DK (1) DK1720571T3 (enExample)
ES (1) ES2389093T3 (enExample)
IL (2) IL177003A0 (enExample)
NZ (1) NZ549328A (enExample)
PL (1) PL1720571T3 (enExample)
PT (1) PT1720571E (enExample)
SI (1) SI1720571T1 (enExample)
WO (1) WO2005074607A2 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
AU2003270330B2 (en) * 2002-09-06 2009-07-30 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component C5
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20070116710A1 (en) * 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
DK1755674T3 (en) * 2004-05-14 2015-02-09 Alexion Pharma Inc PROLONGED SURVIVAL OF A allograft by inhibiting complement activity
US8951522B2 (en) * 2011-04-08 2015-02-10 University Of Leicester Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2006107708A1 (en) * 2005-04-04 2006-10-12 Alexion Pharmaceuticals, Inc. Treatment of disease caused by excess free hemoglobin
HUE026423T2 (en) * 2005-11-04 2016-05-30 Genentech Inc Use of complement biosynthetic pathway inhibitors for treating eye diseases
CA2644020C (en) * 2006-03-02 2016-05-10 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
SI2359834T1 (sl) * 2006-03-15 2017-02-28 Alexion Pharmaceuticals, Inc. Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa
IN2014DN10515A (enExample) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
NZ576195A (en) 2006-10-10 2012-04-27 Az Univ Amsterdam Complement inhibition for improved nerve regeneration
SI2097455T1 (sl) * 2006-11-02 2015-03-31 Genentech, Inc. Humanizirana protitelesa proti faktorju tipa d
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
TWI700293B (zh) 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
PY09026846A (es) * 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
HUE061548T2 (hu) * 2008-11-10 2023-07-28 Alexion Pharma Inc Komplementtel összefüggõ rendellenességek kezelésére szolgáló eljárások és készítmények
AU2010306581B2 (en) * 2009-10-16 2015-03-19 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
US20110124019A1 (en) * 2009-11-25 2011-05-26 The Charlotte-Mecklenburg Hospital Authority Method of using carbonic anhydrase to detect hemolysis
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
EP2545079A2 (en) * 2010-03-11 2013-01-16 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
KR102568454B1 (ko) 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
AU2015230852B2 (en) * 2011-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. High concentration antibody formulations
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
PE20150159A1 (es) 2011-12-21 2015-02-08 Novartis Ag Composiciones y metodos para anticuerpos que actuan sobre el factor p
HK1204693A1 (en) * 2012-03-16 2015-11-27 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
EP2833907B1 (en) * 2012-04-06 2018-02-28 Omeros Corporation Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
US20160051673A1 (en) * 2013-03-29 2016-02-25 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
KR101834469B1 (ko) 2013-08-07 2018-03-06 알렉시온 파마슈티칼스, 인코포레이티드 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질
CA2920666A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
LT3057993T (lt) 2013-10-17 2020-11-25 Omeros Corporation Gydymo būdai būklių, susijusių su nuo masp-2 priklausomu komplemento aktyvinimu
CR20160561A (es) 2014-05-01 2017-05-03 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
TWI656133B (zh) 2014-12-19 2019-04-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
KR101838645B1 (ko) 2014-12-19 2018-03-14 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 그의 사용 방법
JP2018511557A (ja) 2015-01-22 2018-04-26 中外製薬株式会社 ２種以上の抗ｃ５抗体の組み合わせおよび使用方法
JP6944375B2 (ja) * 2015-03-31 2021-10-06 アレクシオン ファーマシューティカルズ， インコーポレイテッド 発作性夜間血色素尿症（ｐｎｈ）患者の亜集団の同定および処置
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
KR102667023B1 (ko) 2016-06-14 2024-05-21 리제너론 파아마슈티컬스, 인크. 항-c5 항체 및 이의 용도
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
IT201600121482A1 (it) * 2016-11-30 2018-05-30 Univ Degli Studi Di Verona Fattore H per l’uso nel trattamento e/o prevenzione della formazione di eterotrombi in pazienti affetti da anemia falciforme
PL3577135T3 (pl) 2017-01-31 2023-12-04 Chugai Seiyaku Kabushiki Kaisha Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
CN120571008A (zh) 2017-12-13 2025-09-02 瑞泽恩制药公司 抗c5抗体组合及其用途
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
CR20210103A (es) 2018-08-01 2021-03-22 Chugai Pharmaceutical Co Ltd Composición farmacéutica para usarse en el tratamiento o prevención de una enfermedad relacionada con c5 y método para tratar o prevenir una enfermedad relacionada con c5
EP4003408A1 (en) 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
WO2021019036A1 (en) 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
DE3924924A1 (de) 1989-07-27 1991-02-07 Goetze Otto Verfahren zum nachweis und/oder der quantitativen bestimmung von komplementpeptid c5a und/oder c5adesarg
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5650825A (en) * 1995-03-31 1997-07-22 Matsushita Electric Corporation Of America Method and apparatus for sending private data instead of stuffing bits in an MPEG bit stream
DE19826743A1 (de) * 1998-06-16 1999-12-23 Bayer Ag Verfahren zur Herstellung von geträgerten Polymerisationskatalysatorsystemen und Verwendung dieser zur Homo- und Copolymerisation ungesättigter Monomere
CA2436671C (en) * 2000-12-05 2015-02-03 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
WO2003081206A2 (en) * 2002-03-18 2003-10-02 Alexion Pharmaceuticals, Inc. Stratification of patient populations having or suspected of having rheumatoid arthritis
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease

Similar Documents

Publication Publication Date Title
JP2007520494A5 (enExample)
JP2010509338A5 (enExample)
Bruce et al. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn--> Asp)
JP5873047B2 (ja) 溶血性疾患の処置方法
JP2011522531A5 (enExample)
CN103052405B (zh) 寡核苷酸螯合物
ES2364118T3 (es) Purificación de factor viii usando una resina de modo mixto o multimodal.
JP2011126917A5 (enExample)
EP2089058A2 (en) Methods of treating hemolytic anemia
JP2004065196A5 (enExample)
US20020090711A1 (en) Process for preparing latent antithrombin III
JP2009530299A5 (enExample)
RU2014144621A (ru) Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения пароксизмальной ночной гемоглобинурии
JP2005522433A5 (enExample)
WO2008092854A3 (en) Papillomavirus e2 polypeptide used for vaccination
Koo et al. Case report. Acute renal cortical necrosis caused by an antifibrinolytic drug (tranexamic acid).
WO2002038610A1 (en) Process for the preparation of latent antithrombin iii
MY197527A (en) Preventive and curative peroxometallate based composition, notably pharmaceutical composition
JP2003507389A5 (enExample)
DE602004023848D1 (de) Von factor vii polypeptiden
WO2004037853A3 (en) Quinolones with anti-hiv activity
JP5475264B2 (ja) シャンプー
CN105714208A (zh) 一种耐蚀高铬铁素体不锈钢及其制备方法与应用
JP2003226945A5 (enExample)
RU2333794C1 (ru) Катализатор для окисления аммиака